JAK Inhibitor Safety: In Perspective
Dr. Roy Fleischmann discusses the clinical context of JAK versus TNF inhibitor safety in the ORAL Surveillance study, including best practices for how and in whom he uses JAK inhibitors. Roy Fleischmann, MD, MACR, is Clinical Professor of Medicine at the University of Texas Southwestern Medical Center, and Co-Medical Director of the Metroplex Clinical Research […]